MA17.04 Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC.

MLA

Novello, S., et al. “MA17.04 Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following CCRT in Limited-Stage SCLC: ADRIATIC.” Journal of Thoracic Oncology, vol. 19, no. 10, Oct. 2024, pp. S124–25. EBSCOhost, https://doi.org/10.1016/j.jtho.2024.09.223.

APA

Novello, S., Cheng, Y., Spigel, D., Fang, J., Chen, Y., Zenke, Y., Lee, K. H., Navarro, A., Buchmeier, E., Chang, J. W.-C., Okamoto, I., Özgüroğlu, M., Kim, Y. J., Hoa, N. T. T., Hashemi, S., Turner, R., Mann, H., Olivo, Y., Jiang, H., & Senan, S. (2024). MA17.04 Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC. Journal of Thoracic Oncology, 19(10), S124–S125. https://doi.org/10.1016/j.jtho.2024.09.223

Chicago

Novello, S., Y. Cheng, D. Spigel, J. Fang, Y. Chen, Y. Zenke, K.H. Lee, et al. 2024. “MA17.04 Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following CCRT in Limited-Stage SCLC: ADRIATIC.” Journal of Thoracic Oncology 19 (10): S124–25. doi:10.1016/j.jtho.2024.09.223.